Bank Julius Baer & Co. Ltd Zurich Cuts Stock Position in iShares Biotechnology ETF (NASDAQ:IBB)

Bank Julius Baer & Co. Ltd Zurich lessened its position in iShares Biotechnology ETF (NASDAQ:IBB) by 2.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 102,897 shares of the financial services provider’s stock after selling 2,074 shares during the quarter. Bank Julius Baer & Co. Ltd Zurich owned approximately 0.22% of iShares Biotechnology ETF worth $15,013,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Concurrent Investment Advisors LLC grew its stake in iShares Biotechnology ETF by 3.4% during the 3rd quarter. Concurrent Investment Advisors LLC now owns 3,712 shares of the financial services provider’s stock worth $541,000 after purchasing an additional 123 shares in the last quarter. Graypoint LLC boosted its position in shares of iShares Biotechnology ETF by 8.4% during the 3rd quarter. Graypoint LLC now owns 1,613 shares of the financial services provider’s stock worth $235,000 after acquiring an additional 125 shares in the last quarter. Beckerman Institutional LLC acquired a new position in shares of iShares Biotechnology ETF during the 3rd quarter worth about $396,000. Objective Capital Management LLC acquired a new position in shares of iShares Biotechnology ETF during the 3rd quarter worth about $445,000. Finally, Sigma Planning Corp boosted its position in shares of iShares Biotechnology ETF by 11.7% during the 3rd quarter. Sigma Planning Corp now owns 7,083 shares of the financial services provider’s stock worth $1,031,000 after acquiring an additional 743 shares in the last quarter. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Performance

NASDAQ:IBB opened at $136.95 on Friday. The stock has a 50-day simple moving average of $136.08 and a 200-day simple moving average of $140.28. The stock has a market cap of $6.47 billion, a P/E ratio of 24.52 and a beta of 0.84. iShares Biotechnology ETF has a 1 year low of $123.60 and a 1 year high of $150.57.

iShares Biotechnology ETF Cuts Dividend

The company also recently announced a dividend, which was paid on Friday, December 20th. Stockholders of record on Tuesday, December 17th were issued a $0.0624 dividend. The ex-dividend date of this dividend was Tuesday, December 17th.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.